Zavegepant

(Zavzpret®)

Zavzpret®

Drug updated on 11/17/2023

Dosage FormNasal spray (intranasal: 10 mg)
Drug ClassCalcitonin gene-related peptide receptor antagonist
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the acute treatment of migraine with or without aura in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Zavzpret (zavegepant) Prescribing Information. 2023Pfizer Laboratories, Div Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses